Skip to main content

Patients Products Pipeline

Team News & Press Releases Publications

Patients Products Pipeline Team News & Press Releases Publications Careers

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Delivering targeted therapies to patients with severe autoimmune disease

Patients Products Pipeline

Team News & Press Releases Publications Careers

Contact Terms of Use Transparency Expanded Access Policy Privacy Policy

This website is intended for informational purposes only, is directed to audiences within the United States, and does not constitute medical advice, a recommendation, or an offer to provide any therapy. Forward-looking statements regarding clinical development reflect current expectations and are subject to change.

© 2026 Priovant Therapeutics, Inc. All rights reserved. info@priovant.com